One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study (PERFUSE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03662919|
Recruitment Status : Recruiting
First Posted : September 10, 2018
Last Update Posted : September 10, 2018
|Condition or disease||Intervention/treatment|
|Arthritis, Rheumatoid Spondylitis, Ankylosing Arthritis, Psoriatic Crohn's Disease Colitis, Ulcerative||Drug: Infliximab|
|Study Type :||Observational|
|Estimated Enrollment :||1500 participants|
|Official Title:||PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi®: a French Cohort Study|
|Actual Study Start Date :||July 2, 2018|
|Estimated Primary Completion Date :||July 1, 2021|
|Estimated Study Completion Date :||July 1, 2021|
Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
Administered as specified in the treatment arm.
Other Name: Flixabi
- Percentage of Participants who are Still Treated by Flixabi at 12 Months [ Time Frame: Up to 12 months ]Percentage of participants, either infliximab naïve or switched from Remicade or CT-P13 to Flixabi, who are still treated with Flixabi at 12 months for RA, AS, PsA, CD (adults and children), and UC (adults and children) will be reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03662919
|Contact: US Biogen Clinical Trial Centeremail@example.com|
|Contact: Global Biogen Clinical Trial Centerfirstname.lastname@example.org|
|Paris, France, 75013|
|Research Site 1||Recruiting|
|Research Site 2||Recruiting|
|Research Site 3||Recruiting|
|Research Site 4||Recruiting|
|Research Site 5||Recruiting|
|Research Site 6||Recruiting|
|Study Director:||Medical Director||Biogen|